Optimizing end points and outcomes in cancer-associated wasting
- PMID: 15838010
- DOI: 10.1200/JCO.2005.05.269
Optimizing end points and outcomes in cancer-associated wasting
Comment on
-
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.J Clin Oncol. 2004 Jun 15;22(12):2469-76. doi: 10.1200/JCO.2004.06.024. J Clin Oncol. 2004. PMID: 15197210 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
